Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells (Q40507294)

21 September 2017

title

Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells (English)

1 reference

21 September 2017

1 reference

Vanessa Desplat

1

1 reference

21 September 2017

Valérie Lagarde

2

1 reference

21 September 2017

Francis Belloc

3

1 reference

21 September 2017

Claudine Chollet

4

1 reference

21 September 2017

Thibaut Leguay

5

1 reference

21 September 2017

Jean-Max Pasquet

6

1 reference

21 September 2017

Vincent Praloran

7

1 reference

21 September 2017

François-Xavier Mahon

8

1 reference

21 September 2017

publication date

1 November 2004

1 reference

21 September 2017

number of pages

11

1 reference

inferred from page(s)

published in

Cytometry Part A

1 reference

21 September 2017

volume

62

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

35-45

1 reference

Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Immunofluorescent quantification of tyrosine phosphorylation of cellular proteins in whole cells by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Phosphotyrosine mapping in Bcr/Abl oncoprotein using phosphotyrosine-specific immonium ion scanning

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20030

7 January 2021

Identifiers

DOI

10.1002/CYTO.A.20030

1 reference

21 September 2017

1 reference